Eptinezumab May Reduce Migraine Frequency in Patients With Chronic and Episodic Migraine

PROMISE-1

Patients in PROMISE-1 had a mean age of about 40, and about 85% were female. They had about 8.5 migraine days per month on average, said Stephen D. Silberstein, MD, Professor of Neurology and Director of the Jefferson Headache Center at Thomas Jefferson University in Philadelphia.

During Weeks 1–12, mean change in monthly migraine days was significantly greater among patients who received eptinezumab (–4.0 with the 30-mg dose, –3.9 with the 100-mg dose, and –4.3 with the 300-mg dose), compared with patients who received placebo (–3.2).

One-year data indicated that the percentage of participants in the trial with 75% and 50% reductions in migraine increased over time. “With each subsequent infusion, there seems to be a cumulative increase in response,” Dr. Silberstein said. At the end of the trial, the proportion of patients in the 300-mg dose group with at least a 75% reduction in migraine days was 52%, whereas the proportion at Month 3 was 37%. The long-term results are encouraging, said Dr. Silberstein.

In PROMISE-1, the most commonly reported adverse events among treated patients were upper respiratory infection (10.3%), nasopharyngitis (6.6%), and sinusitis (3.6%).

—Jake Remaly